122 related articles for article (PubMed ID: 21129814)
1. Impact of death receptor signaling on the malignancy of pancreatic ductal adenocarcinoma.
Röder C; Trauzold A; Kalthoff H
Eur J Cell Biol; 2011; 90(6-7):450-5. PubMed ID: 21129814
[TBL] [Abstract][Full Text] [Related]
2. CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-kappaB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells.
Trauzold A; Wermann H; Arlt A; Schütze S; Schäfer H; Oestern S; Röder C; Ungefroren H; Lampe E; Heinrich M; Walczak H; Kalthoff H
Oncogene; 2001 Jul; 20(31):4258-69. PubMed ID: 11464292
[TBL] [Abstract][Full Text] [Related]
3. Nuclear death receptor TRAIL-R2 inhibits maturation of let-7 and promotes proliferation of pancreatic and other tumor cells.
Haselmann V; Kurz A; Bertsch U; Hübner S; Olempska-Müller M; Fritsch J; Häsler R; Pickl A; Fritsche H; Annewanter F; Engler C; Fleig B; Bernt A; Röder C; Schmidt H; Gelhaus C; Hauser C; Egberts JH; Heneweer C; Rohde AM; Böger C; Knippschild U; Röcken C; Adam D; Walczak H; Schütze S; Janssen O; Wulczyn FG; Wajant H; Kalthoff H; Trauzold A
Gastroenterology; 2014 Jan; 146(1):278-90. PubMed ID: 24120475
[TBL] [Abstract][Full Text] [Related]
4. Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis.
Hinz S; Trauzold A; Boenicke L; Sandberg C; Beckmann S; Bayer E; Walczak H; Kalthoff H; Ungefroren H
Oncogene; 2000 Nov; 19(48):5477-86. PubMed ID: 11114725
[TBL] [Abstract][Full Text] [Related]
5. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family.
Basu A; Castle VP; Bouziane M; Bhalla K; Haldar S
Cancer Res; 2006 Apr; 66(8):4309-18. PubMed ID: 16618756
[TBL] [Abstract][Full Text] [Related]
6. High TRAIL death receptor 4 and decoy receptor 2 expression correlates with significant cell death in pancreatic ductal adenocarcinoma patients.
Sanlioglu AD; Dirice E; Elpek O; Korcum AF; Ozdogan M; Suleymanlar I; Balci MK; Griffith TS; Sanlioglu S
Pancreas; 2009 Mar; 38(2):154-60. PubMed ID: 18981952
[TBL] [Abstract][Full Text] [Related]
7. Subcellular compartmentalization of TNF receptor-1 and CD95 signaling pathways.
Tchikov V; Bertsch U; Fritsch J; Edelmann B; Schütze S
Eur J Cell Biol; 2011; 90(6-7):467-75. PubMed ID: 21144616
[TBL] [Abstract][Full Text] [Related]
8. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells.
Trauzold A; Röder C; Sipos B; Karsten K; Arlt A; Jiang P; Martin-Subero JI; Siegmund D; Müerköster S; Pagerols-Raluy L; Siebert R; Wajant H; Kalthoff H
FASEB J; 2005 Apr; 19(6):620-2. PubMed ID: 15670977
[TBL] [Abstract][Full Text] [Related]
9. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma.
Trauzold A; Siegmund D; Schniewind B; Sipos B; Egberts J; Zorenkov D; Emme D; Röder C; Kalthoff H; Wajant H
Oncogene; 2006 Nov; 25(56):7434-9. PubMed ID: 16751802
[TBL] [Abstract][Full Text] [Related]
10. Catalytically active Yersinia outer protein P induces cleavage of RIP and caspase-8 at the level of the DISC independently of death receptors in dendritic cells.
Gröbner S; Adkins I; Schulz S; Richter K; Borgmann S; Wesselborg S; Ruckdeschel K; Micheau O; Autenrieth IB
Apoptosis; 2007 Oct; 12(10):1813-25. PubMed ID: 17624595
[TBL] [Abstract][Full Text] [Related]
11. Messengers of cell death: apoptotic signaling in health and disease.
Rossi D; Gaidano G
Haematologica; 2003 Feb; 88(2):212-8. PubMed ID: 12604411
[TBL] [Abstract][Full Text] [Related]
12. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
13. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
14. TRAIL signalling: decisions between life and death.
Falschlehner C; Emmerich CH; Gerlach B; Walczak H
Int J Biochem Cell Biol; 2007; 39(7-8):1462-75. PubMed ID: 17403612
[TBL] [Abstract][Full Text] [Related]
15. TRAIL-induced expression of uPA and IL-8 strongly enhanced by overexpression of TRAF2 and Bcl-xL in pancreatic ductal adenocarcinoma cells.
Zhou DH; Yang LN; Roder C; Kalthoff H; Trauzold A
Hepatobiliary Pancreat Dis Int; 2013 Feb; 12(1):94-8. PubMed ID: 23392805
[TBL] [Abstract][Full Text] [Related]
16. Mutations in K-Ras linked to levels of osteoprotegerin and sensitivity to TRAIL-induced cell death in pancreatic ductal adenocarcinoma cells.
Kanzaki H; Ohtaki A; Merchant FK; Greene MI; Murali R
Exp Mol Pathol; 2013 Apr; 94(2):372-9. PubMed ID: 23219833
[TBL] [Abstract][Full Text] [Related]
17. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP
Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649
[TBL] [Abstract][Full Text] [Related]
18. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways.
Schattenberg JM; Schuchmann M; Galle PR
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():213-9. PubMed ID: 21199533
[TBL] [Abstract][Full Text] [Related]
19. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of Par-4 sensitizes TRAIL-induced apoptosis via inactivation of NF-kappaB and Akt signaling pathways in renal cancer cells.
Lee TJ; Jang JH; Noh HJ; Park EJ; Choi KS; Kwon TK
J Cell Biochem; 2010 Apr; 109(5):885-95. PubMed ID: 20127709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
